LUCD vs. MODD, CODX, LNSR, MDAI, NMTC, FEMY, GBS, CTCX, DRIO, and ICU
Should you be buying Lucid Diagnostics stock or one of its competitors? The main competitors of Lucid Diagnostics include Modular Medical (MODD), Co-Diagnostics (CODX), LENSAR (LNSR), Spectral AI (MDAI), NeuroOne Medical Technologies (NMTC), Femasys (FEMY), GBS (GBS), Carmell (CTCX), DarioHealth (DRIO), and SeaStar Medical (ICU). These companies are all part of the "surgical & medical instruments" industry.
Lucid Diagnostics (NASDAQ:LUCD) and Modular Medical (NASDAQ:MODD) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, community ranking, valuation, risk, profitability, institutional ownership, media sentiment, earnings and dividends.
74.0% of Lucid Diagnostics shares are held by institutional investors. Comparatively, 27.5% of Modular Medical shares are held by institutional investors. 4.8% of Lucid Diagnostics shares are held by insiders. Comparatively, 32.3% of Modular Medical shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Modular Medical has lower revenue, but higher earnings than Lucid Diagnostics. Modular Medical is trading at a lower price-to-earnings ratio than Lucid Diagnostics, indicating that it is currently the more affordable of the two stocks.
Lucid Diagnostics currently has a consensus target price of $2.75, indicating a potential upside of 310.39%. Modular Medical has a consensus target price of $4.25, indicating a potential upside of 183.33%. Given Lucid Diagnostics' higher possible upside, analysts clearly believe Lucid Diagnostics is more favorable than Modular Medical.
Modular Medical has a net margin of 0.00% compared to Lucid Diagnostics' net margin of -2,169.07%. Modular Medical's return on equity of -235.93% beat Lucid Diagnostics' return on equity.
Lucid Diagnostics has a beta of 1.63, suggesting that its share price is 63% more volatile than the S&P 500. Comparatively, Modular Medical has a beta of 0.43, suggesting that its share price is 57% less volatile than the S&P 500.
Lucid Diagnostics received 23 more outperform votes than Modular Medical when rated by MarketBeat users. However, 100.00% of users gave Modular Medical an outperform vote while only 59.52% of users gave Lucid Diagnostics an outperform vote.
In the previous week, Lucid Diagnostics and Lucid Diagnostics both had 3 articles in the media. Modular Medical's average media sentiment score of 0.76 beat Lucid Diagnostics' score of -0.50 indicating that Modular Medical is being referred to more favorably in the news media.
Summary
Lucid Diagnostics and Modular Medical tied by winning 7 of the 14 factors compared between the two stocks.
Get Lucid Diagnostics News Delivered to You Automatically
Sign up to receive the latest news and ratings for LUCD and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding LUCD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Lucid Diagnostics Competitors List
Related Companies and Tools
